Physician profile
Mustafa Abas
NPI 1720392988
$521.41
in general payments reported to CMS, 2019-2025
15 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.86 · 2022: $16.17 · 2023: $15.94 · 2024: $135 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414 · Education: $73.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.66 |
| Education | $73.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $93.78 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $85.35 | 2024-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $70.40 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Baxter Healthcare | $32.40 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $31.31 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $22.16 | 2025 | Yupelri |
| Amgen INC. | $20.65 | 2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $19.98 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $18.64 | 2024 | Keytruda |
| United Therapeutics Corporation | $16.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.67 | 2025 | Jascayd |
| Astrazeneca Pharmaceuticals LP | $13.52 | 2025 | Breztri |
| Mylan Specialty L.P. | $13.40 | 2024 | Yupelri |
| Inogen, INC. | $12.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Abas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.